Cited by 896Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCerebrospinal fluid and hydrocephalus

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain

Open access

Tapiola, Tero, Alafuzoff, Irina, Herukka, Sanna-Kaisa, Parkkinen, Laura, Hartikainen, Päivi, Soininen, Hilkka, Pirttilä, Tuula·2009·Archives of Neurology

DOI 10.1001/archneurol.2008.596

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: There is a clear need to develop an objective diagnostic test for Alzheimer disease (AD). Changes in the levels of cerebrospinal fluid (CSF) tau protein and beta-amyloid 42 (Abeta42) peptide in patients with AD have been well documented, but the relationship between these biomarkers and neuropathologic changes in the brain is not established. OBJECTIVE: To study the relationship between antemortem CSF biomarker levels and Alzheimer-type neuropathologic changes in the brain. DESIGN: Cross-sectional study to correlate levels of CSF Abeta42, total tau, and phosphorylated tau protein with neuropathologic changes in the brain. SETTING: Academic research. Patients The study included 123 patients (79 with clinically diagnosed AD, 29 with other dementia, and 15 with other neurologic disease). All underwent clinical evaluation and provided antemortem lumbar CSF samples, and neuropathologic data were collected from September 11, 1990, to March 13, 2003, in the Department of Neuroscience and Neurology, University of Kuopio, Kuopio, Finland. MAIN OUTCOME MEASURES: Levels of CSF Abeta42, total tau, and phosphorylated tau protein were measured using standard commercial immunoassays. Neuropathologic evaluations included the classic silver impregnation method and immunohistochemistry for Abeta, hyperphosphorylated tau, and alpha-synuclein. RESULTS: Cerebrospinal fluid Abeta42 and tau protein levels were related to amyloid load and the presence of neurofibrillary pathologic abnormalities in the brain. Cerebrospinal fluid Abeta42 level correlated inversely with total Abeta load in the brain, and CSF tau level correlated with results of immunohistochemistry for hyperphosphorylated tau and with the presence of neocortical neurofibrillary tangles. In multivariate logistic regression analysis, the number of neuritic plaques in the brain remained a significant predictor of decreased CSF Abeta42 level and of increased CSF tau level. Based on the ratio of phosphorylated tau level to Abeta42 level, sensitivity was 91.6%, and specificity was 85.7%, with an overall accuracy of 90.2% for the presence of pathologic neuritic plaque in the brain. CONCLUSIONS: Cerebrospinal fluid Abeta42 and tau proteins are biomarkers of AD-associated pathologic changes in the brain. The combination of abnormally low CSF Abeta42 level and abnormally high CSF tau level predicted the presence of AD pathologic features with high accuracy. This combination assay may be helpful in diagnosing the presence of AD pathologic changes in the brain.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/archneurol.2008.596

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. L., & Stadlan, E. (2011) · Neurology · doi:10.1212/01.wnl.0000400650.92875.cf · Cited by 9,882
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Self-citation
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700

Show all 29 references

Sorted by citations

Items 401–500 of 895

Cerebrospinal Fluid Biomarkers for the Diagnosis of Prodromal Alzheimer’s Disease in Amnestic Mild Cognitive Impairment
Park, J. E., Choi, K. Y., Kim, B. C., Choi, S., Song, M., Lee, J. J., Kim, J., Song, H., Kim, H., Ha, J., et al. (2019) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000496920 · Cited by 30
Type-2-Diabetes Alters CSF but Not Plasma Metabolomic and AD Risk Profiles in Vervet Monkeys
Kavanagh, K., Day, S. M., Pait, M. C., Mortiz, W. R., Newgard, C. B., Ilkayeva, O., McClain, D. A., & Macauley, S. L. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00843 · Cited by 30
Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer’s Disease
Robinson, R. A. S., Amin, B., & Guest, P. C. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-52479-5_2 · Cited by 29
Biomarkers in Alzheimer’s, Frontotemporal, Lewy Body, and Vascular Dementias
Koenig, A. M., Nobuhara, C. K., Williams, V. J., & Arnold, S. E. (2018) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20170048 · Cited by 29
Hollow core photonic crystal fiber-assisted Raman spectroscopy as a tool for the detection of Alzheimer’s disease biomarkers
Eravuchira, P. J., Banchelli, M., D’Andrea, C., de Angelis, M., Matteini, P., & Gannot, I. (2020) · Journal of Biomedical Optics · doi:10.1117/1.jbo.25.7.077001 · Cited by 28
Alzheimer disease: From biomarkers to diagnosis
Dubois, B., Epelbaum, S., Santos, A., Stefano, F. D., Julian, A. G., Michon, A., Sarazin, M., & Hampel, H. J. (2013) · Revue Neurologique · doi:10.1016/j.neurol.2013.07.016 · Cited by 34
The CSF p-tau181/Aβ42 Ratio Offers a Good Accuracy “In Vivo” in the Differential Diagnosis of Alzheimer’s Dementia
Santangelo, R., Dell’Edera, A., Sala, A., Cecchetti, G., Masserini, F., Caso, F., Pinto, P., Leocani, L., Falautano, M., Passerini, G., et al. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190725150836 · Cited by 27
Fluid Candidate Biomarkers for Alzheimer’s Disease: A Precision Medicine Approach
Prete, E. D., Beatino, M. F., Campese, N., Giampietri, L., Siciliano, G., Ceravolo, R., & Baldacci, F. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040221 · Cited by 29
The Diagnostic Value of Exosome-Derived Biomarkers in Alzheimer's Disease and Mild Cognitive Impairment: A Meta-Analysis
Xing, W., Gao, W., Lv, X., Xu, X., Zhang, Z., Yan, J., Mao, G., & Bu, Z. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.637218 · Cited by 27
Fractal motor activity regulation and sex differences in preclinical Alzheimer's disease pathology
Gao, L., Li, P., Gaba, A., Musiek, E. S., Ju, Y. S., & Hu, K. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12211 · Cited by 29
Evaluation of ATN PD Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease
Cousins, K. A. Q., Irwin, D. J., Tropea, T. F., Rhodes, E., Phillips, J. S., Chen‐Plotkin, A. S., Brumm, M. C., Coffey, C. S., Kang, J., Simuni, T., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000208033 · Cited by 27
Identification and modification of amyloid-independent phenotypes of APOE4 mice
DiBattista, A. M., Dumanis, S. B., Newman, J., & Rebeck, G. W. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.04.014 · Cited by 28
Intranetwork and internetwork connectivity in patients with Alzheimer disease and the association with cerebrospinal fluid biomarker levels
Weiler, M., de Campos, B. M., Teixeira, C. V. L., Casseb, R. F., Carletti‐Cassani, A. F. M. K., Vicentini, J. E., Magalhães, T. N. C., Talib, L. L., Forlenza, O. V., & Balthazar, M. L. F. (2017) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.160190 · Cited by 27
Effects of NR1H3 Genetic Variation on the Expression of Liver X Receptor α and the Progression of Alzheimer's Disease
Natunen, T., Martiskainen, H., Sarajärvi, T., Helisalmi, S., Pursiheimo, J., Viswanathan, J., Laitinen, M. H., Mäkinen, P. M., Kauppinen, T., Rauramaa, T. H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080700 · Cited by 26
Self-citation
Analysis of Cerebrospinal Fluid and [ 11 C]PIB PET Biomarkers for Alzheimer’s Disease with Updated Protocols
Wang, M. J., Yi, S., Han, J.-Y., Park, Y. H., Jang, J., Chun, I. K., Giau, V. V., Bagyinszky, E., Lim, K., Kang, S. M., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160143 · Cited by 26
Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer’s disease
Lin, S.-Y., Lin, K., Lin, P.-C., Huang, C.-C., Chang, C., Lee, Y., Hsiao, I., Yen, T., Huang, W.-S., Yang, B., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0566-0 · Cited by 26
High Performance Detection of Alzheimer’s Disease Biomarkers Based on Localized Surface Plasmon Resonance
Nhiem, L. T., & Park, S. (2020) · Journal of Industrial and Engineering Chemistry · doi:10.1016/j.jiec.2020.07.051 · Cited by 27
An overview of biomarkers in Alzheimer′s disease
Mathuranath, P. S., & Wattamwar, P. R. (2010) · Annals of Indian Academy of Neurology · doi:10.4103/0972-2327.74256 · Cited by 28
Mild cognitive impairment (part 2): biological markers for diagnosis and prediction of dementia in Alzheimer's disease
Forlenza, O. V., Diniz, B. S., Teixeira, A. L., Stella, F., & Gattaz, W. F. (2013) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2012-3505 · Cited by 31
Revista Española de Geriatría y Gerontología
Santos, R. P., Torres, C. F., Martín‐Arranz, M. D., de Parga, J. M. S., & Martínez, M. A. (2016) · Cited by 26
Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer’s Disease Dementia
Mazzeo, S., Santangelo, R., Bernasconi, M. P., Cecchetti, G., Fiorino, A., Pinto, P., Passerini, G., Falautano, M., Comı, G., & Magnani, G. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160360 · Cited by 26
Peptide Antibodies in Clinical Laboratory Diagnostics
Trier, N. H., & Houen, G. (2017) · Advances in clinical chemistry · doi:10.1016/bs.acc.2017.01.002 · Cited by 26
Multimodal PET Imaging of Amyloid and Tau Pathology in Alzheimer Disease and Non–Alzheimer Disease Dementias
Xia, C., & Dickerson, B. C. (2017) · PET Clinics · doi:10.1016/j.cpet.2017.02.005 · Cited by 28
Cerebrospinal fluid markers analysis in the differential diagnosis of dementia with Lewy bodies and Parkinson’s disease dementia
Gmitterová, K., Gawinecka, J., Llorens, F., Varges, D., Valkovič, P., & Zerr, I. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0928-9 · Cited by 26
Stability of Plasma Amyloid-β 1–40, Amyloid-β 1–42, and Total Tau Protein over Repeated Freeze/Thaw Cycles
Liu, H.-C., Chiu, M., Lin, C., & Yang, S. (2020) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000506278 · Cited by 26
Neuro-Retina Might Reflect Alzheimer’s Disease Stage
Santangelo, R., Huang, S., Bernasconi, M. P., Falautano, M., Comı, G., Magnani, G., & Leocani, L. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200043 · Cited by 28
Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease—From Brain Starch to Bench and Bedside
Pawlowski, M., Meuth, S., & Duning, T. (2017) · Diagnostics · doi:10.3390/diagnostics7030042 · Cited by 25
CSF Biomarkers of Alzheimer Disease in Patients With Concomitant α-Synuclein Pathology
Cousins, K. A. Q., Arezoumandan, S., Shellikeri, S., Ohm, D., Shaw, L. M., Grossman, M., Wolk, D., McMillan, C. T., Chen-Plotkin, A., Lee, E., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000201202 · Cited by 25
The discriminative capacity of CSF β-amyloid 42 and Tau in neurodegenerative diseases in the Chinese population
Ye, L., Li, X., Zhang, Y.-B., Cheng, H.-R., Ma, Y., Chen, D.-F., Tao, Q., Li, H., & Wu, Z. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116756 · Cited by 25
Electroacupuncture improves cognitive deficits and insulin resistance in an OLETF rat model of Al/D-gal induced aging model via the PI3K/Akt signaling pathway
Huang, X., Huang, K., Li, Z., Bai, D., Yan, H., Wu, Q., Wei, Y., Xu, N., Pan, Y., & Zhang, L. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146834 · Cited by 25
Onset of Preclinical Alzheimer Disease in Monozygotic Twins
Konijnenberg, E., Tomassen, J., den Braber, A., ten Kate, M., Yaqub, M. M., Mulder, S. D., Nivard, M. G., Vanderstichele, H., Lammertsma, A. A., Teunissen, C. E., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26048 · Cited by 25
Amyloid and Tau in Alzheimer’s Disease: Biomarkers or Molecular Targets for Therapy? Are We Shooting the Messenger?
Kumar, A., Nemeroff, C. B., Cooper, J. J., Widge, A. S., Rodríguez, C. I., Carpenter, L. L., & McDonald, W. M. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.19080873 · Cited by 25
The role of exosomes in adult neurogenesis: implications for neurodegenerative diseases
Yu, Z., Teng, Y., Yang, J., & Yang, L. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.379036 · Cited by 26
Overlap between Frontotemporal Dementia and Alzheimer's Disease: Cerebrospinal Fluid Pattern and Neuroimaging Study
Padovani, A., Premi, E., Pilotto, A., Gazzina, S., Cosseddu, M., Archetti, S., Cancelli, V., Paghera, B., & Borroni, B. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121969 · Cited by 25
Brain perfusion SPECT correlates with CSF biomarkers in Alzheimer’s disease
Habert, M., de Souza, L. C., Lamari, F., Daragon, N., Désarnaud, S., Jardel, C., Dubois, B., & Sarazin, M. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1285-8 · Cited by 25
Could Clinical Profile Influence CSF Biomarkers in Early-onset Alzheimer Disease?
Koric, L., Félician, O., Guedj, É., Hubert, A.-M., Mancini, J., Boucraut, J., & Ceccaldi, M. P. (2010) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181d712d9 · Cited by 26
Cerebrospinal fluid profile of amyloid β42 (Aβ42), hTau and ubiquitin in North Indian Alzheimer's disease patients
Kandimalla, R. J. L., Prabhakar, S., Binukumar, B. K., Wani, W. Y., Sharma, D. R., Grover, V., Bhardwaj, N., Jain, K., & Gill, K. D. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.06.075 · Cited by 26
Low normal cerebrospinal fluid Aβ42 levels predict clinical progression in nondemented subjects
Tijms, B. M., Bertens, D., Slot, R. E. R., Gouw, A. A., Teunissen, C. E., Scheltens, P., van der Flier, W. M., & Visser, P. J. (2017) · Annals of Neurology · doi:10.1002/ana.24921 · Cited by 25
Role of Body-Fluid Biomarkers in Alzheimer’s Disease Diagnosis
Nguyen, T. T., Ta, Q. T. H., Nguyen, T. K. O., Nguyen, T. K. O., & Giau, V. V. (2020) · Diagnostics · doi:10.3390/diagnostics10050326 · Cited by 25
MFG-E8 (LACTADHERIN): a novel marker associated with cerebral amyloid angiopathy
Marazuela, P., Solé, M., Bonaterra‐Pastra, A., Pizarro, J., Camacho, J., Martínez-Sáez, E. A., Kuiperij, H. B., Verbeek, M. M., de Kort, A. M., Schreuder, F. H. B. M., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01257-9 · Cited by 24
Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective
Ricci, M., Cimini, A., Camedda, R., Chiaravalloti, A., & Schillaci, O. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313002 · Cited by 24
Clinical Neuroproteomics and Biomarkers
Shoemaker, L. D., Achrol, A. S., Sethu, P., Steinberg, G. K., & Chang, S. D. (2011) · Neurosurgery · doi:10.1227/neu.0b013e3182333a26 · Cited by 24
Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease Families with PSEN1 Mutations
Fortea, J., Lladó, A., Bosch, B., Antonell, A., Oliva, R., Molinuevo, J. L., & Sánchez‐Valle, R. (2011) · Neurodegenerative Diseases · doi:10.1159/000322229 · Cited by 24
What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France
Cognat, E., Mouton‐Liger, F., Troussière, A., Wallon, D., Dumurgier, J., Magnin, É., Duron, E., Gabelle, A., Croisile, B., Sayette, V. D. L., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-026380 · Cited by 24
How many patients are eligible for disease-modifying treatment in Alzheimer’s disease? A French national observational study over 5 years
Epelbaum, S., Paquet, C., Hugon, J., Dumurgier, J., Wallon, D., Hannequin, D., Jonveaux, T., Besozzi, A., Pouponneau, S., Hommet, C., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-029663 · Cited by 24
Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers
Stewart, T., Initiative, A. F. T. A. D. N., Shi, M. Y., Mehrotra, A., Aro, P., Soltys, D., Kerr, K. F., Zabetian, C. P., Peskind, E. R., Taylor, P., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190069 · Cited by 24
Differences in brain cholesterol metabolism and insulin in two subgroups of patients with different CSF biomarkers but similar white matter lesions suggest different pathogenic mechanisms
Besga, A., Cedazo-Mı́nguez, Á., Kåreholt, I., Solomon, A., Björkhem, I., Winblad, B. G., Leoni, V., Hooshmand, B., Spulber, G., González-Pinto, A. M., et al. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.01.017 · Cited by 24
Core cerebrospinal fluid biomarker profile in anti-LGI1 encephalitis
Lardeux, P., Fourier, A., Peter, E., Dorey, A., Muñiz‐Castrillo, S., Vogrig, A., Picard, G., Rogemond, V., Verdurand, M., Formaglio, M., et al. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10642-2 · Cited by 23
Cerebrospinal fluid and blood biomarkers in the diagnostic assays of Alzheimer’s disease
Zhang, L., Liang, X., Zhang, Z., & Luo, H. (2021) · Journal of Innovative Optical Health Sciences · doi:10.1142/s1793545822300014 · Cited by 24
Age, sex and APOE-ε4 modify the balance between soluble and fibrillar β-amyloid in non-demented individuals: topographical patterns across two independent cohorts
Cacciaglia, R., Salvadó, G., Molinuevo, J. L., Shekari, M., Falcón, C., Operto, G., Suárez‐Calvet, M., Milà‐Alomà, M., Sala, A., Rodriguez‐Vieitez, E., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01436-7 · Cited by 23
Risk factors of cognitive impairment: Impact of decline in oral function
Takahashi, T., Hatta, K., & Ikebe, K. (2023) · Japanese Dental Science Review · doi:10.1016/j.jdsr.2023.06.006 · Cited by 23
Amyloidogenic Nanoplaques in Blood Serum of Patients with Alzheimer’s Disease Revealed by Time-Resolved Thioflavin T Fluorescence Intensity Fluctuation Analysis
Tiiman, A., Jelić, V., Jarvet, J., Järemo, P., Bogdanović, N., Rigler, R. W., Terenius, L. Y., Gräslund, A., & Vukojević, V. B. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181144 · Cited by 23
Elevated cerebrospinal fluid total tau in former professional athletes with multiple concussions
Taghdiri, F., Multani, N., Tarazi, A., Naeimi, S. A., Khodadadi, M., Esopenko, C., Green, R., Colella, B., Wennberg, R. A., Mikulis, D. J., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007608 · Cited by 27
Biomarker profiles of Alzheimer’s disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau
Lafirdeen, A. S. M., Cognat, E., Sabia, S., Hourrègue, C., Lilamand, M., Dugravot, A., Bouaziz-Amar, É., Laplanche, J., Hugon, J., Singh‐Manoux, A., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217026 · Cited by 24
Metabolic Profiles Help Discriminate Mild Cognitive Impairment from Dementia Stage in Alzheimer’s Disease
Jääskeläinen, O., Hall, A., Tiainen, M., van Gils, M., Lötjönen, J. M. P., Kangas, A. J., Helisalmi, S., Pikkarainen, M., Hallikainen, M., Koivisto, A. M., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191226 · Cited by 23
Self-citation
Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians
Rosa‐Neto, P., Hsiung, G. R., Masellis, M., & participants, O. B. O. T. C. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt223 · Cited by 24
Codon 129 polymorphism and the E200K mutation do not affect the cellular prion protein isoform composition in the cerebrospinal fluid from patients with Creutzfeldt–Jakob disease
Schmitz, M., Schlomm, M., Hasan, B., Beekes, M., Mitrova, E., Korth, C., Breil, A., Carimalo, J., Gawinecka, J., Varges, D., et al. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07224.x · Cited by 22
Lesion Topography and Microscopic White Matter Tract Damage Contribute to Cognitive Impairment in Symptomatic Carotid Artery Disease
Meng, D., Hosseini, A. A., Simpson, R. J., Shaikh, Q., Tench, C. R., Dineen, R. A., & Auer, D. P. (2016) · Radiology · doi:10.1148/radiol.2016152685 · Cited by 22
Herpes simplex virus alters Alzheimer's disease biomarkers ‐ A hypothesis paper
Goldhardt, O., Freiberger, R., Dreyer, T. F., Willner, L., Yakushev, I. Y., Ortner, M., Förstl, H., Diehl‐Schmid, J., Milz, E., Priller, J., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12834 · Cited by 25
Emerging Roles of Cells and Molecules of Innate Immunity in Alzheimer’s Disease
Tamburini, B., Badami, G. D., Manna, M. P. L., Azgomi, M. S., Caccamo, N., & Dieli, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241511922 · Cited by 22
Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease
Rosén, C., & Zetterberg, H. (2013) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32835f6747 · Cited by 23
Cerebrospinal fluid Aβ 42 levels and APP processing pathway genes in Parkinson's disease
Bekris, L. M., Tsuang, D. W., Peskind, E. R., Yu, C., Montine, T. J., Zhang, J., Zabetian, C. P., & Leverenz, J. B. (2015) · Movement Disorders · doi:10.1002/mds.26172 · Cited by 22
Granular expression of prolyl-peptidyl isomerase PIN1 is a constant and specific feature of Alzheimer’s disease pathology and is independent of tau, Aβ and TDP-43 pathology
Dakson, A., Yokota, O., Esiri, M. M., Bigio, E. H., Horan, M. A., Pendleton, N., Richardson, A. M. T., Neary, D., Snowden, J. S., Robinson, A., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0798-y · Cited by 22
Cerebrospinal fluid markers detect Alzheimer's disease in nonamnestic dementia
Oboudiyat, C., Gefen, T. D., Varelas, E. A., Weıntraub, S., Rogalski, E. J., Bigio, E. H., & Mesulam, M. M. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.01.006 · Cited by 22
Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults
Idland, A., Sala‐Llonch, R., Watne, L. O., Brækhus, A., Hansson, O., Blennow, K., Zetterberg, H., Sørensen, Ø., Walhovd, K. B., Wyller, T. B., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.04.002 · Cited by 22
A Reliable and Rapid Language Tool for the Diagnosis, Classification, and Follow-Up of Primary Progressive Aphasia Variants
Epelbaum, S., Saade, Y. M., Roze, C. F., Roze, E., Ferrieux, S., Arbizu, C., Nogues, M., Azuar, C., Dubois, B., du Montcel, S. T., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2020.571657 · Cited by 20
The search for a convenient procedure to detect one of the earliest signs of Alzheimer's disease: A systematic review of the prediction of brain amyloid status
Ashford, M. T., Veitch, D. P., Neuhaus, J. M., Nosheny, R. L., Tosun, D., & Weiner, M. W. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12253 · Cited by 23
Pleiotropy in the Presence of Allelic Heterogeneity: Alternative Genetic Models for the Influence of APOE on Serum LDL, CSF Amyloid-β42, and Dementia
Bennet, A. M., Reynolds, C. A., Gatz, M., Blennow, K., Pedersen, N. L., & Prince, J. A. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100864 · Cited by 22
Jatamansinol from Nardostachys jatamansi (D.Don) DC. Protects Aβ42-Induced Neurotoxicity in Alzheimer's Disease Drosophila Model
Anupama, K. P., Olakkaran, S., Antony, A., Raghu, S. V., & Gurushankara, H. P. (2022) · NeuroToxicology · doi:10.1016/j.neuro.2022.02.011 · Cited by 21
Who Needs Cerebrospinal Biomarkers? A National Survey in Clinical Practice
Troussière, A., Wallon, D., Mouton‐Liger, F., Yatimi, R., Robert, P. H., Hugon, J., Hannequin, D., Pasquier, F., & Paquet, C. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132672 · Cited by 21
Immuno-PCR-based quantification of multiple phosphorylated tau-epitopes linked to Alzheimer’s disease
Singer, D. L., Soininen, H. S., Alafuzoff, I. I., & Hoffmann, R. (2009) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-009-3208-8 · Cited by 21
Self-citation
Cross-sectional and longitudinal associations of motor fluctuations and non-motor predominance with cerebrospinal τ and Aβ as well as dementia-risk in Parkinson's disease
Modreanu, R., Cerquera‐Cleves, C., Martı́, M. J., Ríos, J., Sánchez‐Gómez, A., Cámara, A., Fernández, M., & Compta, Y. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.12.064 · Cited by 21
Cerebrospinal Fluid Biomarker-Based Diagnosis of Sporadic Creutzfeldt-Jakob Disease: A Validation Study for Previously Established Cutoffs
Llorens, F., Karch, A., Golańska, E., Schmitz, M., Lange, P., Sikorska, B., Liberski, P. P., & Zerr, I. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000454802 · Cited by 21
Urine dicarboxylic acids change in pre-symptomatic Alzheimer’s disease and reflect loss of energy capacity and hippocampal volume
Castor, K., Shenoi, S., Edminster, S. P., Tran, T. T., King, K. S., Chui, H. C., Pogoda, J. M., Fonteh, A. N., & Harrington, M. G. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231765 · Cited by 22
Correlation between Cognitive Impairment and Peripheral Biomarkers - Significance of Phosphorylated Tau and Amyloid-β in Alzheimer’s Disease: A New Insight
Sarkar, S., Bhui, U., Kumar, B., Ashique, S., Kumar, P., Sharma, H., Bhowmick, M., Pal, R., & Kumar, T. (2024) · Current Psychiatry Research and Reviews · doi:10.2174/0126660822329981241007105405 · Cited by 25
Clinical guidelines «Cognitive disorders in the elderly and senile persons»
Tkacheva, O. N., Yahno, N. N., Незнанов, Н. Г., Шпорт, С. В., Shamalov, N. A., Levin, O. S., Kostyuk, G. P., Gusev, E. I., Martynov, M. Y., Si, G., et al. (2025) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2025125337 · Cited by 22
MRI-based Alzheimer’s disease-resemblance atrophy index in the detection of preclinical and prodromal Alzheimer’s disease
Liu, W., Initiative, A. D. N., Au, L. W. C., Abrigo, J., Luo, Y., Wong, A., Lam, B. Y. K., Fan, X., Kwan, P. W.-L., Ma, H. W., et al. (2021) · Aging · doi:10.18632/aging.203082 · Cited by 20
The Role of Plasma Neurofilament Light Protein for Assessing Cognitive Impairment in Patients With End-Stage Renal Disease
Hou, Y., Huang, C., Lu, C., Zheng, C., Lin, Y., Lu, K., Chung, Y.-L., & Chen, R. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.657794 · Cited by 20
Blood-based Aβ42 increases in the earliest pre-pathological stage before decreasing with progressive amyloid pathology in preclinical models and human subjects: opening new avenues for prevention
Lucena, P. B., Vanherle, S., Lodder, C., de Ravé, M. G., Stancu, I., Lambrichts, I., Vangheluwe, R., Bruffaerts, R., & Dewachter, I. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02458-9 · Cited by 22
Using Redox Proteomics to Gain New Insights into Neurodegenerative Disease and Protein Modification
Cadenas-Garrido, P., Schonvandt-Alarcos, A., Herrera‐Quintana, L., Vázquez‐Lorente, H., Santamaría-Quiles, A., de Francisco, J. R., Moya-Escudero, M., Martín‐Oliva, D., Martín-Guerrero, S. M., Rodríguez-Santana, C., et al. (2024) · Antioxidants · doi:10.3390/antiox13010127 · Cited by 20
Increased expression of calponin-3 in epileptic patients and experimental rats
Han, Y., Yin, H., Xu, Y., Zhu, Q., Luo, J., Wang, X., & Chen, G. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.11.014 · Cited by 20
Functional correlates of t-Tau, p-Tau and Aβ1–42 amyloid cerebrospinal fluid levels in Alzheimer’s disease
Chiaravalloti, A., Martorana, A., Koch, G., Toniolo, S., Biagio, D. D., Pietro, B. D., & Schillaci, O. (2015) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000272 · Cited by 20
Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges
Kim, D., Kim, Y. S., Shin, D. W., Park, C., & Kang, J.-H. (2016) · Journal of Clinical Neurology · doi:10.3988/jcn.2016.12.4.381 · Cited by 20
The Rationale Behind the New Alzheimer’s Disease Conceptualization: Lessons Learned During the Last Decades
Molinuevo, J. L., Minguillón, C., Rami, L., & Gispert, J. D. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170698 · Cited by 21
Usefulness of CSF Biomarkers in Predicting the Progression of Amnesic and Nonamnesic Mild Cognitive Impairment to Alzheimer’s Disease
Ortega, R. L., Dakterzada, F., Arias, A. M., Blasco, E., Naudí, A., Purroy, F. F., & Piñol‐Ripoll, G. (2019) · Current Aging Science · doi:10.2174/1874609812666190112095430 · Cited by 23
Benchmarking biomarker‐based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem
Rosén, C., Farahmand, B. Y., Skillbäck, T. B., Nägga, K., Mattsson, N., Kilander, L., Religa, D., Wimo, A. B., Blennow, K., Winblad, B. G., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.04.007 · Cited by 20
Evidence of Syntaxin 1A Involvement in Migraine Susceptibility
Lemos, C., Pereira-Monteiro, J. M., Mendonça, D. M., Ramos, E. M., Barros, J., Sequeiros, J., Alonso, I. D. C. M. P., & Sousa, A. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.37 · Cited by 20
CSF Aβ 1-42 Levels and Glucose Metabolism in Alzheimer's Disease>
Dumurgier, J., Paquet, C., Peoc’h, K., Lapalus, P., Mouton‐Liger, F., Benisty, S., Chasseigneaux, S., Chabriat, H., & Hugon, J. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111007 · Cited by 21
Personalized health care beyond oncology: new indications for immunoassay‐based companion diagnostics
Batrla, R., & Jordan, B. W. M. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12754 · Cited by 19
Effect of amyloid‐β ( A β) immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase (GSK )‐3β
Amin, J., Paquet, C., Baker, A., Asuni, A. A., Love, S., Holmes, C., Hugon, J., Nicoll, J. A. R., & Boche, D. (2014) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12205 · Cited by 19
CSF Biomarkers of Alzheimer’s Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design
Fagan, A. M. (2014) · Advances in Geriatrics · doi:10.1155/2014/302712 · Cited by 21
Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Patients with Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis with the C9ORF72 Repeat Expansion
Kämäläinen, A., Herukka, S., Hartikainen, P. H., Helisalmi, S., Moilanen, V., Knuuttila, A., Jansson, L., Tienari, P. J., & Remes, A. M. (2015) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000371704 · Cited by 19
Self-citation
Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum
Solé‐Padullés, C., Lladó, A., Bartrés‐Faz, D., Fortea, J., Sánchez‐Valle, R., Bosch, B., Antonell, A., Molinuevo, J. L., & Rami, L. (2011) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2010.12.001 · Cited by 19
Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study
Paquet, C., Magnin, É., Wallon, D., Troussière, A., Dumurgier, J., Jager, A., Bellivier, F., Bouaziz-Amar, É., Blanc, F., Beaufils, É., et al. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0192-z · Cited by 19
Applications of Biotechnology in Neurology
Jain, K. K. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-272-8 · Cited by 19
Ganglion Cell Layer Thinning in Alzheimer’s Disease
López‐de‐Eguileta, A., Cerveró, A., de Sabando, A. R., Sánchez‐Juan, P., & Casado, A. (2020) · Medicina · doi:10.3390/medicina56100553 · Cited by 19
A cortical form of CADASIL with cerebral Aβ amyloidosis
Paquet, C., Jouvent, É., Miné, M., Vital, A., Hugon, J., Chabriat, H., & Gray, F. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0758-y · Cited by 19
Severe Brain Metabolic Decreases Associated with REM Sleep Behavior Disorder in Dementia with Lewy Bodies
Iaccarino, L., Marelli, S., Iannaccone, S., Magnani, G., Ferini‐Strambi, L., & Perani, D. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151000 · Cited by 19
Enfermedad de Alzheimer. Guía de práctica clínica
Allegri, R., Arizaga, R. L., Bavec, C. V., Colli, L. P., Demey, I., Fernández, M. C., Frontera, S. A., Garau, M. L., Jiménez, J. J., Golimstok, Á., et al. (2011) · Neurología Argentina · doi:10.1016/s1853-0028(11)70026-x · Cited by 25
Biomarkers of Alzheimer’s Disease and Cerebrovascular Lesions and Clinical Progression in Patients with Subjective Cognitive Decline: A Systematic Review
Scarth, M., Rissanen, I. L., Scholten, R. J. P. M., & Geerlings, M. I. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210218 · Cited by 18

Authors: Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T.
Affiliations: University of Eastern Finland (FI)
ORCID: Alafuzoff, Irina
Herukka, Sanna-Kaisa
Parkkinen, Laura
Hartikainen, Päivi
Soininen, Hilkka
Venue: Archives of Neurology
Publisher: American Medical Association (AMA)
Published: 2009-03-01
Volume: 66
Issue: 3
Pages: 382-9
ISSN: 0003-9942 (ISSN-L)
DOI: 10.1001/archneurol.2008.596
OpenAlex: W2075193321
Cited by: 896
References: 29
Citations by year: 2026: 18 · 2025: 27 · 2024: 45 · 2023: 27 · 2022: 34 · 2021: 78 · 2020: 89 · 2019: 75 · 2018: 60 · 2017: 59 · 2016: 51 · 2015: 65 · 2014: 48 · 2013: 63 · 2012: 41
FWCI: 32.16
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Archives of Neurology (publishedVersion)
PubMed (publishedVersion)
Funders: Kuopion Yliopistollinen Sairaala
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
Keywords: Alzheimer's disease, cerebrospinal fluid biomarkers, amyloid-beta 42, tau protein, phosphorylated tau, amyloid plaques, neurofibrillary tangles, diagnostic accuracy, lumbar CSF, neurodegeneration, alpha-synuclein, postmortem neuropathology, biomarker ratios, sensitivity and specificity
MeSH terms: Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Brain, Cross-Sectional Studies, Dementia, Female, Humans, Immunoassay, Male, Nervous System Diseases, Peptide Fragments, Retrospective Studies, ROC Curve, Logistic Models, Amyloid beta-Peptides, Silver Staining, tau Proteins, Statistics, Nonparametric, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks